Australia
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:00
1920
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...
2024-01-24 21:30
1705
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...
2024-01-18 10:31
1389
Style3D Research Shines the Show with additional Two Papers Accepted at SIGGRAPH ASIA 2023 on Cloth Simulation Innovations
SYDNEY, Jan. 10, 2024 /PRNewswire/ -- The electrifying stage of SIGGRAPH Asia 2023 witnessed Style3D Research's triumphant unveiling of two groundbreaking research papers through captivating oral presentations. This pinnacle gathering, renowned as a global hub for computer graphics, provided the ...
2024-01-11 02:00
1745
Seeing Machines unveils latest Guardian technology at CES 2024
- Guardian is the company's world-leading Aftermarket Driver Monitoring System for commercial vehicles and is currently connected to 54,000 vehicles globally - The new version includes Drowsiness Detection with refined microsleep detection and eye-gaze tracking to protect drivers fro...
2024-01-09 21:00
1640
Canadian Solar's e-STORAGE to Deliver 220 MWh DC of Battery Storage Solutions to Epic Energy's Mannum Project in South Australia
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc
2024-01-08 20:05
1376
Recurrent Energy Completes Sale of 100 MW/200 MWh Battery Energy Storage Project in South Australia to Epic Energy
GUELPH, ON, Jan. 8, 2024 /PRNewswire/ -- Canadian Solar Inc.
2024-01-08 20:00
1595
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN
ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...
2024-01-04 04:30
1921
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...
2023-12-24 17:53
2775
Following a digital Rebrand, Little Black Book Looks Back at a Decade of Exponential Growth and Record Turnover
* LBB reports continued growth in business in the UK and an acceleration in growth internationally with increased business in theUSA, Canada, Australia, India and Germany. * A record turnover for the business of £3.2m in 2022, with a turnover of around £4m forecast in 2023. * The world's le...
2023-12-20 04:16
1772
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Highlights: * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...
2023-12-18 19:00
1295
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
2023-12-11 22:30
1811
IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending
MELBOURNE, Australia, Dec. 6, 2023 /PRNewswire/ -- IonOpticks, the world leader in high performance liquid chromatography for mass spectrometry, is proud to announce an exciting collaboration with Newomics Inc. that has produced an interface solution for their flagship Aurora Series columns and A...
2023-12-07 07:04
1690
Registrational Phase III CLARIFY trial in prostate cancer commences
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its r...
2023-11-30 22:16
1530
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...
2023-11-30 21:59
1653
Leading AI decisioning platform Rich Data Co successfully raises $17.5 million in Series B round to accelerate North America expansion
SYDNEY, Nov. 29, 2023 /PRNewswire/ -- Rich Data Co
2023-11-30 07:13
1448
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with67Cu-SAR-bisPSMA at the highest dose level of 12GBq. * No dose limiting toxicit...
2023-11-29 21:58
1584
Telstra Broadcast Services and BT Announce Strategic Alliance to Enhance Global Network Connectivity
Initial five-year agreement delivers expanded media and broadcast network footprint acrossAsia-Pacific and key regions worldwide, with enhanced access to global markets SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Telstra Broadcast Services (TBS) and BT have entered into an initial five-year strateg...
2023-11-21 13:30
1452
First Subject Enrolled in Phase 1 Study of MRX-5
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as ＂MicuRx＂) announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...
2023-11-20 18:34
1499
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...
2023-11-14 08:27
1395
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 287 media titles]
2025-01-14 21:00
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20545
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6515
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5849
Boqii Announces ADS Ratio Change
2025-01-11 05:30
5014
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
5005
